BTG2

Across TCGA pan-cancer cohorts, BTG2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BTG2 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher BTG2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BTG2 expression acts as an unfavorable survival marker.

LUSC, DLBC, and UCEC are the cancer types where BTG2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.011	0.776	<.001	36	view →
DLBC	DFS	Median	II,III,IV	0.464	0.951	.006	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
LUAD	OS	Median	All	0.341	0.685	.033	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BTG2–LUSC (OS)

Open the LUSC breakdown →